Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant
WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung
cancer(NSCLC).